Company

Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc., based in San Francisco, develops and sells therapies for hematologic disorders and cancer.

About

Founded in 1996 by Tullio Favretto and headquartered in San Francisco, US, Rigel Pharmaceuticals develops and commercializes therapies for hematologic disorders and cancer. Its products include TAVALISSE (fostamatinib), GAVRETO (pralsetinib) and REZLIDHIA (belantamab mafodotin). The company reported revenue of USD 144.90 mn and EBITDA of USD 26.42 mn for fiscal 2024, and it raised USD 130 mn in a PIPE round on May 1, 2011. It is listed as Public.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in